SVF
Level D· Preclinical EvidenceAnimal Study

Decellularized tendon scaffold seeded with adipose-derived MSCs and supplemented with G-CSF injection promotes tendon repair in a rat model.

Khaled H., Zayed M., Kim B., Jeong BH., Oh SI.

Animal Study on Tendon Injury, Chronic Inflammation, published in Biomed Pharmacother (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Biomed Pharmacother (2026)
Country
France
Reported sample size
—
PMID
42531629
DOI
10.1016/j.biopha.2026.119798

Abstract (original English)

Tendon injuries cause pain and functional limitations, posing a clinical burden due to poor healing and recurrence. Combining mesenchymal stem cells (MSCs), tissue-specific extracellular matrix (ECM) scaffolds, and bioactive factors may enhance tendon regeneration. This study investigated integrating adipose-derived MSCs (AD-MSCs) seeded on a decellularized tendon scaffold (DTS) with G-CSF injection for tendon repair. DTS was prepared from rat Achilles tendons through freeze-thaw cycles and sodium dodecyl sulfate decellularization, preserving ECM structure. In vitro, AD-MSC viability, tenogenic gene expression, and scratch wound closure were assessed in response to G-CSF ± DTS. In vivo, a rat Achilles tendon defect model included: control (CTL), DTS, DTS with G-CSF, and DTS and AD-MSCs with G-CSF. After 6 weeks, histology, immunohistochemistry, collagen quantification, gene expression, and immunofluorescence analyses were performed. DTS maintained AD-MSC viability and tenogenic differentiation in vitro by upregulating SCX, COL1, and TN-C. G-CSF (1000 ng/mL) enhanced AD-MSC-mediated wound closure in the presence of DTS extract. In vivo, DTS with AD-MSCs and G-CSF showed organized collagen alignment, reduced cellularity and inflammation, increased collagen deposition, and the highest total collagen content. Furthermore, it exhibited upregulation of SCX, TN-C, COL1, THBS-4, and DC

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
Ankle & FootTendon InjuryChronic Inflammation
View on PubMedDOI

Related research